Primary Aldosteronism Market Research Report – Forecast till 2030

Primary Aldosteronism Market research report, Type (type I, type II), Indication (heart attack, kidney failure, stroke), by Diagnosis (blood test, imaging), Treatment (surgery, aldosterone antagonists), End User (hospitals) - forecast till 2030

ID: MRFR/Pharma/4075-HCR | February 2021 | Region: Global | 90 Pages         

TABLE OF CONTENT


Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restrains

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Primary Aldosteronism Market, by Type

6.1 Introduction

6.2 Type I

Market Estimates & Forecast, 2020 – 2027

6.3 Type II

Market Estimates & Forecast, 2020 – 2027

Chapter 7. Global Primary Aldosteronism Market, by Indications

7.1 Introduction

7.2 Heart Attack

Market Estimates & Forecast, 2020 – 2027

7.3 Kidney Failure

Market Estimates & Forecast, 2020 – 2027

7.4 Stroke

Market Estimates & Forecast, 2020 – 2027

7.5 Others

Chapter 8. Global Primary Aldosteronism Market, by Diagnosis

8.1 Introduction

8.2 Diagnosis

Market Estimates & Forecast, 2020 – 2027

8.2.1 Blood Test

8.2.1.1 Aldosterone Profiling

8.2.1.2 Renin Profiling

8.2.1.3 Others

8.2.2 Imaging

8.2.2.1 Computed Tomography (CT)

8.2.2.2 Positron Emission Tomography (PET)

8.2.2.3 Others

Chapter 9 Global Primary Aldosteronism Market, by End User

9.1 Introduction

9.2 Surgery

Market Estimates & Forecast, 2020 – 2027

9.3 Aldosterone Antagonists

Market Estimates & Forecast, 2020 – 2027

9.3.1 Spironolactone

9.3.2 Eplerenone

9.3.3 Others

Chapter 10 Global Primary Aldosteronism Market, by End User

10.1 Introduction

10.2 End User

Market Estimates & Forecast, 2020 – 2027

10.2.1 Hospitals & Clinics

10.2.2 Research Organization

10.2.3 Academic Institutes

10.2.4 Others

Chapter 11. Global Primary Aldosteronism Market, by Region

11.1 Introduction

11.2 America

11.2.1 North America

11.2.1.1 U.S.

11.2.1.1 Canada

11.2.2 South America

11.3 Europe

11.3.1 Western Europe

11.3.1.1 Germany

11.3.1.2 France

11.3.1.3 Italy

11.3.1.4 Spain

11.3.1.5 U.K

11.3.1.6 Rest of Western Europe

11.3.2 Eastern Europe

11.4 Asia Pacific

11.4.1 Japan

11.4.2 China

11.4.3 India

11.4.4 Australia

11.4.5 Republic of Korea

11.4.6 Rest of Asia Pacific

11.5 The Middle East & Africa

11.5.1 United Arab Emirates

11.5.2 Saudi Arabia

11.5.3 Oman

11.5.4 Kuwait

11.5.5 Qatar

11.5.6 Rest of the Middle East & Africa

Chapter 12 Company Landscape

12.1 Introduction

12.2 Market Share Analysis

12.3 Key Development & Strategies

12.3.1 Key Developments

Chapter 13 Company Profiles

13.1 Pfizer Inc.

13.1.1 Company Overview

13.1.2 Product Overview

13.1.3 Financials

13.1.4 Key Developments

13.1.5 SWOT Analysis

13.2 Sun Pharmaceutical Industries Ltd.

13.2.1 Company Overview

13.2.2 Product Overview

13.2.3 Financial Overview

13.2.4 Key Developments

13.2.5 SWOT Analysis

13.3 Bristol Laboratories Ltd

13.3.1 Company Overview

13.3.2 Product Overview

13.3.3 Financial Overview

13.3.4 Key Development

13.3.5 SWOT Analysis

13.4 CMP Pharma

13.4.1 Company Overview

13.4.2 Product/Business Segment Overview

13.4.3 Financial Overview

13.4.4 Key Development

13.4.5 SWOT Analysis

13.5 Koninklijke Philips N.V.

13.5.1 Company Overview

13.5.2 Product Overview

13.5.3 Financial overview

13.5.4 Key Developments

13.5.5 SWOT Analysis

13.6 GE Healthcare

13.6.1 Company Overview

13.6.2 Product Overview

13.6.3 Financial Overview

13.6.4 Key Developments

13.6.5 SWOT Analysis

13.7 Siemens AG

13.7.1 Overview

13.7.2 Product Overview

13.7.3 Financials

13.7.4 Key Developments

13.7.5 SWOT Analysis

13.8 Shimadzu Corporation

13.8.1 Overview

13.8.2 Product Overview

13.8.3 Financials

13.8.4 Key Developments

13.8.5 SWOT Analysis

13.9 Canon Inc.

13.9.1 Overview

13.9.2 Product Overview

13.9.3 Financials

13.9.4 Key Developments

13.9.5 SWOT Analysis

13.10 Others

Chapter 14 MRFR Conclusion

14.1 Key Findings

14.1.1 From CEO’s View Point

14.1.2 Unmet Needs of the Market

14.2 Key Companies to Watch

14.3 Prediction of Pharmaceutical industry

Chapter 15 Appendix

LIST OF TABLES

Table 1 Primary Aldosteronism Industry Synopsis, 2020 – 2027

Table 2 Global Primary Aldosteronism Market Estimates and Forecast, 2020 – 2027, (USD Million)

Table 3 Global Primary Aldosteronism Market by Region, 2020 – 2027, (USD Million)

Table 4 Global Primary Aldosteronism Market by Type, 2020 – 2027, (USD Million)

Table 5 Global Primary Aldosteronism Market by Indications, 2020 – 2027, (USD Million)

Table 6 Global Primary Aldosteronism Market by Diagnosis, 2020 – 2027, (USD Million)

Table 7 Global Primary Aldosteronism Market by Treatment, 2020 – 2027, (USD Million)

Table 8 Global Primary Aldosteronism Market by End User, 2020 – 2027, (USD Million)

Table 9 North America Primary Aldosteronism Market by Type, 2020 – 2027, (USD Million)

Table 10 North America Primary Aldosteronism Market by Indications, 2020 – 2027, (USD Million)

Table 11 North America Primary Aldosteronism Market by Diagnosis, 2020 – 2027, (USD Million)

Table 12 North America Primary Aldosteronism Market by Treatment, 2020 – 2027, (USD Million)

Table 13 North America Primary Aldosteronism Market by End User, 2020 – 2027, (USD Million)

Table 14 US Primary Aldosteronism Market by Type, 2020 – 2027, (USD Million)

Table 15 US Primary Aldosteronism Market by Indications, 2020 – 2027, (USD Million)

Table 16 US Primary Aldosteronism Market by Diagnosis, 2020 – 2027, (USD Million)

Table 17 US Primary Aldosteronism Market by Treatment, 2020 – 2027, (USD Million)

Table 18 US Primary Aldosteronism Market by End User, 2020 – 2027, (USD Million)

Table 19 Canada Primary Aldosteronism Market by Type, 2020 – 2027, (USD Million)

Table 20 Canada Primary Aldosteronism Market by Indications, 2020 – 2027, (USD Million)

Table 21 Canada Primary Aldosteronism Market by Diagnosis, 2020 – 2027, (USD Million)

Table 22 Canada Primary Aldosteronism Market by Treatment, 2020 – 2027, (USD Million)

Table 23 Canada Primary Aldosteronism Market by End User s, 2020 – 2027, (USD Million)

Table 24 South America Primary Aldosteronism Market by Type, 2020 – 2027, (USD Million)

Table 25 South America Primary Aldosteronism Market by Indications, 2020 – 2027, (USD Million)

Table 26 South America Primary Aldosteronism Market by Diagnosis, 2020 – 2027, (USD Million)

Table 27 South America Primary Aldosteronism Market by Treatment, 2020 – 2027, (USD Million)

Table 28 South America Primary Aldosteronism Market by End User, 2020 – 2027, (USD Million)

Table 29 Europe Primary Aldosteronism Market by Type, 2020 – 2027, (USD Million)

Table 30 Europe Primary Aldosteronism Market by Indications, 2020 – 2027, (USD Million)

Table 31 Europe Primary Aldosteronism Market by Diagnosis, 2020 – 2027, (USD Million)

Table 32 Europe Primary Aldosteronism Market by Treatment, 2020 – 2027, (USD Million)

Table 33 Europe Primary Aldosteronism Market by End User, 2020 – 2027, (USD Million)

Table 34 Western Primary Aldosteronism Europe Market by Type, 2020 – 2027, (USD Million)

Table 35 Western Europe Primary Aldosteronism Market by Indications, 2020 – 2027, (USD Million)

Table 36 Western Europe Primary Aldosteronism Market by Diagnosis, 2020 – 2027, (USD Million)

Table 37 Western Europe Primary Aldosteronism Market by Treatment, 2020 – 2027, (USD Million)

Table 38 Western Europe Primary Aldosteronism Market by End User, 2020 – 2027, (USD Million)

Table 39 Eastern Europe Primary Aldosteronism Market by Type, 2020 – 2027, (USD Million)

Table 40 Eastern Europe Primary Aldosteronism Market by Indications, 2020 – 2027, (USD Million)

Table 41 Eastern Europe Primary Aldosteronism Market by Diagnosis, 2020 – 2027, (USD Million)

Table 42 Eastern Europe Primary Aldosteronism Market by Treatment, 2020 – 2027, (USD Million)

Table 43 Eastern Europe Primary Aldosteronism Market by End User, 2020 – 2027, (USD Million)

Table 44 Asia Pacific Primary Aldosteronism Market by Type, 2020 – 2027, (USD Million)

Table 45 Asia Pacific Primary Aldosteronism Market by Indications, 2020 – 2027, (USD Million)

Table 46 Asia Pacific Primary Aldosteronism Market by Diagnosis, 2020 – 2027, (USD Million)

Table 47 Asia Pacific Primary Aldosteronism Market by Treatment, 2020 – 2027, (USD Million)

Table 48 Asia Pacific Primary Aldosteronism Market by End User, 2020 – 2027, (USD Million)

Table 49 Middle East & Africa Primary Aldosteronism Market by Type, 2020 – 2027, (USD Million)

Table 50 Middle East & Africa Primary Aldosteronism Market by Indications, 2020 – 2027, (USD Million)

Table 51 Middle East & Africa Primary Aldosteronism Market by Diagnosis, 2020 – 2027, (USD Million)

Table 52 Middle East & Africa Primary Aldosteronism Market by Treatment, 2020 – 2027, (USD Million)

Table 53 Middle East & Africa Primary Aldosteronism Market by End User, 2020 – 2027, (USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Global Primary Aldosteronism Market

Figure 3 Segmentation Market Dynamics for Global Primary Aldosteronism Market

Figure 4 Global Primary Aldosteronism Market Share, by Type 2020

Figure 5 Global Primary Aldosteronism Market Share, by Indications 2020

Figure 6 Global Primary Aldosteronism Market Share, by Diagnosis 2020

Figure 7 Global Primary Aldosteronism Market Share, by Treatment 2020

Figure 8 Global Primary Aldosteronism Market Share, by End User, 2020

Figure 9 Global Primary Aldosteronism Market Share, by Region, 2020

Figure 10 North America Primary Aldosteronism Market Share, by Country, 2020

Figure 11 Europe Primary Aldosteronism Market Share, by Country, 2020

Figure 12 Asia Pacific Primary Aldosteronism Market Share, by Country, 2020

Figure 13 Middle East & Africa Primary Aldosteronism Market Share, by Country, 2020

Figure 14 Global Primary Aldosteronism Market: Company Share Analysis, 2020 (%)

Figure 15 Pfizer Inc.: Key Financials

Figure 16 Pfizer Inc.: Segmental Revenue

Figure 17 Pfizer Inc.: Geographical Revenue

Figure 18 Sun Pharmaceutical Industries Ltd.: Key Financials

Figure 19 Sun Pharmaceutical Industries Ltd.: Segmental Revenue

Figure 20 Sun Pharmaceutical Industries Ltd.: Geographical Revenue

Figure 21 Bristol Laboratories Ltd: Key Financials

Figure 22 Bristol Laboratories Ltd: Segmental Revenue

Figure 23 Bristol Laboratories Ltd: Geographical Revenue

Figure 24 CMP Pharma.: Key Financials

Figure 25 CMP Pharma.: Segmental Revenue

Figure 26 CMP Pharma.: Geographical Revenue

Figure 27 Koninklijke Philips N.V.: Key Financials

Figure 28 Koninklijke Philips N.V.: Segmental Revenue

Figure 29 Koninklijke Philips N.V.: Geographical Revenue

Figure 30 GE Healthcare: Key Financials

Figure 31 GE Healthcare: Segmental Revenue

Figure 32 GE Healthcare: Geographical Revenue

Figure 33 Siemens AG: Key Financials

Figure 34 Siemens AG: Segmental Revenue

Figure 35 Siemens AG: Geographical Revenue

Figure 36 Shimadzu Corporation: Key Financials

Figure 37 Shimadzu Corporation: Segmental Revenue

Figure 38 Shimadzu Corporation: Geographical Revenue

Figure 39 Canon Inc.: Key Financials

Figure 40 Canon Inc.: Segmental Revenue

Figure 41 Canon Inc.: Geographical Revenue

Primary Aldosteronism Market Speak to Analyst Request a Free Sample

Primary Aldosteronism Market Overview 


The primary aldosteronism market size is projected to grow by 8.60%. Aldosteronism is a hormone in the human body. The adrenal glands regulate sodium and potassium in the blood through this hormone. However, in some individuals the secretion of this hormone is high. Due to this blood pressure, sodium and blood volume is high. The treatment of this condition is essential as the risk of stroke and heart disease is high. The availability of aldosteronism treatment is high in recent years. Earlier, the identification of this condition is low. Awareness about the disease is less in earlier years. However, drugs and treatments available for the disease are surging. The oral salt loading test is growing every year. The easy access for the treatment of primary is increasing growth for primary aldosteronism market.


 Due to the high secretion of this hormone kidney, salvia glands, sweat glands have high salt content. Today, the pharmacies supplying the aldosteronism drugs are rising. Also, many regions have favourable scenarios that will bring positive changes in the market. Extensive research is happening in the aldosteronism market. Due to noncancerous tumours and defects in genes is another underlying condition in the market. Hyperactivity and hyper conditions are some of the other conditions of this disorder. The non-surgical segment of the primary aldosteronism market is witnessing high growth in the forecast period. 


Covid analysis 


The outbreak of covid 19 is causing plenty of difficulties in global industries. The treatment of Aldosteronism is witnessing a downfall in the forecast period. During this period, covid patient care is the prime focus of hospitals. Treating new covid cases and reducing the death rate is the major health sector operations. Further, the development of a vaccine is a crucial operation. The treatment for the disorders is declining in this period.


 The patients visiting hospitals for other conditions have significantly reduced during this period. The test, screening, treatment, drugs market of Aldosteronism is facing a downfall during this pandemic. Due to global lockdowns and restrictions treatment for this condition is delaying. The supply chain distributions to transport treatment product related to this condition is diminishing. However, Aldosteronism is undergoing extensive research. More study about the condition will lead to plenty of future developments. 


Market dynamics 



  • Crucial market drivers 


The prevalence of primary aldosteronism is a crucial driver for the primary aldosteronism market. A sedentary lifestyle is a reason for more aldosteronism. It is a hormonal disorder that is stirred by plenty of factors. High blood pressure and hypertension are triggering Primary Aldosteronism. Also, busy lifestyle stressful condition is another factor for the disorder. In the upcoming years, the case of Aldosteronism is expected to rise immensely. The growing geriatric population is another demand driving factor of the primary aldosteronism market. The age’s population is often prone to hormonal imbalance. Also, the easy indication methods of this condition in aged individuals are rising. 


It is a crucial driver that increases the adoption rate of the primary aldosteronism market. Awareness about Aldosteronism is a major diver for the primary aldosteronism market. Aldosteronism can lead to other health complications without proper treatment. High blood pressure, heart disease, kidney problems and other issues are common with this commission. More awareness about the disease is diving most of the population for the Aldosteronism test. Also, the testing and treatments for Aldosteronism are high. Due to this, the demand rate is continuously surging. All these factors will contribute to the high profitability of the primary aldosteronism market. The exposure for the market will reach its peak in upcoming years. 



  • Market growth opportunities 


The efforts to invest in new drugs for Aldosteronism are rising in many regions. It is a significant factor that creates more development possibilities for the primary aldosteronism market. The launch of new therapeutic drugs by key players will increase the growth rate. All these developments in the market are possible through high research and development. The R&D investments for the market are rising. Also, Aldosteronism is a less studied condition. More research will lead to a better understanding of this disease. Also, efficient treatment is possible through this research. 


The growing research in the market will escalate the overall expansion rate in the forecast period. Due to more awareness, the high adoption of the treatment will bring favourable changes in the primary aldosteronism market. Also, the Aldosteronism market provides both surgical and non-surgical treatments. It offers plenty of choices for the patients to choose from. However, the developments in non-surgical Aldosteronism are high in the forecast period. All these factors will bring exceptional, primary aldosteronism market growth possibilities.  



  • The market restraints 


The lack of awareness about the primary Aldosteronism market is a major restraint. Aldosteronism is a condition that is less known in developing nations and many regions. Many think of Aldosteronism as a normal rise in blood pressure. However, no proper treatment for the disorder can lead to an increased imbalance in hormones. More research and awareness programs for the market are happening in the forecast period. 


It is expected to increase the effects of this medical condition. As per the primary aldosteronism market analysis, less awareness will lead to low adoption of Aldosteronism treatment. Also, the lack of proper treatment in several health sectors for the condition is another restraint in the primary aldosteronism market. These factors can hamper the overall demand in the forecast period. 



  • The market challenges 


There are side effects for primary Aldosteronism treatment. These side effects pose a challenge to the primary Aldosteronism market. Especially, therapeutics drugs can affect the patient with visible side effects. As it is a hormonal condition, the hormones in the body can change. Due to this breast enlargement, menstrual irregularities and impotence are common. 


These side effects hinder the demand for the market in the forecast period. Also, there are several risks related to the other forms of Aldosteronism treatment. Excessive bleeding due to surgical Aldosteronism is a concerning factor of the primary aldosteronism market. These side effects create fear in patients to adapt to the treatment. These side effects and market challenges can hamper the overall expansion rate. 



  • Cumulative growth analysis 


Growth of the primary aldosteronism is constantly surging in the forecast period. Several factors stir the overall growth of the primary aldosteronism market. The increasing awareness about this disease is leading to more adoption. Also, the treatments available for aldosteronism are growing in many regions. 


Further, the growth of the geriatric population is a major cause of the high demand for aldosteronism treatment and surgeries. The R&D investments will bring a favourable impact on the primary aldosteronism market. With increasing research, product launches and innovations are expected to create promising growth possibilities for the market. The primary aldosteronism market trends remain positive. 



  • Value chain analysis 


North America is an excelling regional player of the primary aldosteronism market. The developed health infrastructure in this region creates massive demand. The patient base is wide in this region. Also, high health expenditure leads to more growth in the aldosteronism market. 


It is a region having a favourable market condition. Production of drugs, therapies, and treatments for aldosteronism is high. The awareness about this condition is higher in America. Also, it is a region that has advanced treatment for aldosteronism. All these factors double the growth of the overall aldosteronism market in North America. 


Segment overview 


By treatment type 



  • Potassium-sparing diuretics

  • Surgical aldosteronism treatment

  • Calcium-channel blockers

  • Endocrine surgery

  • Mineralocorticoid receptor antagonists

  • Adrenalectomy

  • Drugs

  • Non-Surgical aldosteronism treatment

  • Drugs

  • Palliative care


By end-users 



  • Ambulatory surgical centres 

  • Clinics 

  • Hospitals 

  • Pharmacy 

  • retail


Competitive landscape 


The competition in the primary aldosteronism treatment industry is moderate in the forecast period. In the upcoming years, the entry of new key players is expected in the market. It can intensify the competition in the primary aldosteronism market. Easy treatment, low-cost drugs are the key strategies of market players. Also, market acquisition, expansion and partnerships will happen in the market. 


Regional analysis 


The aldosteronism market is segmented into Asia Pacific, Europe and North America. North America is a predominant regional player with higher growth. The prevalence of tumour and aldosteronism cases is higher in this region. Further, the availability of drugs and treatment is higher in this region. The well-established health facilities lead to exceptional treatment for the disease. Europe is another largest key player with high demand. 


The health expenditure is higher in Europe. It leads to more research and development in the region. The awareness about aldosteronism is less in Asia pacific. However, the market expansion rate and adoption of treatments are higher. India, chain and jape are the key contributors to the market. 


The key players of the primary aldosteronism market are 



  1. Canon Inc 

  2. Pfizer Inc.

  3. Shimadzu Corporation 

  4. Sun Pharmaceutical Industries Ltd.

  5. Shimadzu Corporation

  6. Bristol Laboratories Ltd

  7. Siemens AG

  8. Bristol Laboratories Ltd

  9. GE Healthcare

  10. Koninklijke Philips N.V.

  11. CMP Pharma


Recent developments 



  1. North America is launching new innovative aldosteronism treatments and drugs.  



  1. There are plenty of collaborations and acquisitions happening in the Asia Pacific region. 


Report overview 



  1. Market overview highlights 

  2. Analysis based upon COVID 19

  3. Explanation upon the Market Dynamics

  4. Value chain analysis

  5. Market segmentation overview

  6. The regional analysis

  7. Competitive landscape analysis

  8. Recent Developments



Report Scope:
Report Attribute/Metric Details
  Market Size   2030: Significant Value
  CAGR   8.60% (2020-2030)
  Base Year   2019
  Forecast Period   2020-2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Type, Indications, Diagnosis, Treatment and End users
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Pfizer Inc. (U.S.), Sun Pharmaceutical Industries Ltd. (India), Bristol Laboratories Ltd (England), CMP Pharma. (U.S.), Koninklijke Philips N.V. (The Netherlands), GE Healthcare (U.K), Siemens AG (Germany), Shimadzu Corporation (Japan), Canon Inc. (Japan), and others.
  Key Market Opportunities   New product launches and R&D Amongst major key Players
  Key Market Drivers

  • Increasing prevalence of primary aldosteronism
  • The growing geriatric population


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    primary aldosteronism market is projected to grow at approximately 8.60% CAGR during the assessment period (2020-2030).

    Increasing prevalence of the condition and the rising per capita healthcare expenditure, are major tailwinds pushing the growth of the primary aldosteronism market.

    Lack of awareness and risks involved with the corrective surgeries, such as excessive bleeding, infection, and anesthesia reaction, are major growth impeder for the primary aldosteronism market.

    North America holds the largest share in the primary aldosteronism market, followed by Europe and the Asia Pacific, respectively.

    Pfizer Inc. (U.S.), Bristol Laboratories Ltd (UK), Sun Pharmaceutical Industries Ltd. (India), CMP Pharma. (U.S.), Siemens AG (Germany), Shimadzu Corporation (Japan), Koninklijke Philips N.V. (The Netherlands), Canon Inc. (Japan), and GE Healthcare (UK), are some of the top players operating in the primary aldosteronism market.